Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3938577 vs Degludec in Type 2 Diabetes
NCT07215312Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of LY3938577 in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Oct 2025; status: active, not recruiting.
02
Drugs
LY3938577
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07215312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215312.